Evidence map›Paper›PMID 30536746›Full record

Trial reportJournal of diabetes investigation2019

Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial.

Hideka Inoue, Katsutaro Morino, Satoshi Ugi, Sachiko Tanaka-Mizuno, Keiko Fuse, Itsuko Miyazawa, Keiko Kondo, Daisuke Sato, Natsuko Ohashi, Shogo Ida and 7 more

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of diabetes investigation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 9 pooled it
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 9 syntheses or guidelines pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Hideka InoueDepartment of Medicine, Shiga University of Medical Science, Otsu, Shiga, Japan.
Katsutaro MorinoDepartment of Medicine, Shiga University of Medical Science, Otsu, Shiga, Japan.ORCID https://orcid.org/0000-0003-2420-3817
Satoshi UgiDepartment of Medicine, Shiga University of Medical Science, Otsu, Shiga, Japan.
Sachiko Tanaka-MizunoDepartment of Medical Statistics, Shiga University of Medical Science, Otsu, Shiga, Japan.
Keiko FuseDepartment of Medicine, Shiga University of Medical Science, Otsu, Shiga, Japan.
Itsuko MiyazawaDepartment of Medicine, Shiga University of Medical Science, Otsu, Shiga, Japan.
Keiko KondoDepartment of Public Health, Shiga University of Medical Science, Otsu, Shiga, Japan.
Daisuke SatoDepartment of Medicine, Shiga University of Medical Science, Otsu, Shiga, Japan.
Natsuko OhashiDepartment of Medicine, Shiga University of Medical Science, Otsu, Shiga, Japan.
Shogo IdaDepartment of Medicine, Shiga University of Medical Science, Otsu, Shiga, Japan.
Osamu SekineDepartment of Medicine, Shiga University of Medical Science, Otsu, Shiga, Japan.
Masahiro YoshimuraDepartment of Radiology, Shiga University of Medical Science, Otsu, Shiga, Japan.
Kiyoshi MurataDepartment of Radiology, Shiga University of Medical Science, Otsu, Shiga, Japan.
Katsuyuki MiuraDepartment of Public Health, Shiga University of Medical Science, Otsu, Shiga, Japan.
Hisatomi ArimaFaculty of Medicine, Department of Preventive Medicine and Public Health, Fukuoka University, Fukuoka, Japan.
Hiroshi MaegawaDepartment of Medicine, Shiga University of Medical Science, Otsu, Shiga, Japan.
SUMS-ADDIT-1 Research group
Shiga University of Medical Science · JPFukuoka University · JP

Funding

Astellas Pharma
6 · The paper itself

Abstract

AIMS/

introductionSodium-glucose cotransporter 2 inhibitors reduce bodyweight (BW) by creating a negative energy balance. Previous reports have suggested that this BW reduction is mainly loss of body fat and that ~20% of the reduction is lean mass. However, the effects of sodium-glucose cotransporter 2 inhibitors on BW and body composition remain unclear. We examined these effects in Japanese patients with type 2 diabetes mellitus treated with insulin. MATERIALS AND

methodsIn this open-label, randomized controlled trial, 49 overweight patients (body mass index ≥23 kg/m

resultsBW change was significantly larger in the ipragliflozin group than in the control group (-2.78 vs -0.22 kg, P < 0.0001). Total fat mass was reduced evenly in the arms, lower limbs and trunk in the ipragliflozin group. Total muscle mass and bone mineral content were maintained, but muscle mass in the arms might have been affected by ipragliflozin treatment.

conclusionsIpragliflozin treatment for 24 weeks resulted in reduced BW, mainly from fat mass loss. Muscle mass and bone mineral content were maintained. Further study is necessary to elucidate the long-term effects of ipragliflozin.

Indexed as

Adipose TissueAdultAgedBiomarkersBody CompositionBody WeightDiabetes Mellitus, Type 2Drug Therapy, CombinationFemaleFollow-Up StudiesGlucosidesHumansHypoglycemic AgentsInsulinMaleMiddle AgedBiomarkersGlucosidesHypoglycemic AgentsInsulinipragliflozinSodium-Glucose Transporter 2 InhibitorsThiophenesBodyweightSodium-glucose cotransporter 2 inhibitorTreatment drug

Identifiers

PMID30536746
PMCPMC6626939
OpenAlexW2904323762

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.